Boston Scientific(BSX) - 2024 Q2 - Earnings Call Presentation

Financial Performance - Net sales increased by 14.5% as reported, with operational growth of 16.1% and organic growth of 14.7% year-over-year[9] - Reported earnings per share (EPS) were $0.22, compared to $0.18 in Q2 2023, while adjusted EPS reached $0.62, up from $0.53 in Q2 2023[10] - The company's Q2 2024 reported net sales reached $4.120 billion[16] - MedSurg reported net sales of $1.483 billion, a 9% increase year-over-year[19] - Cardiovascular reported net sales of $2.637 billion, a 17.8% increase year-over-year[22] Segment Performance - Endoscopy global net sales increased by 7.1% as reported, 8.4% operationally, and 7.9% organically[20] - Urology global net sales increased by 8.2% as reported and 9.1% operationally and organically[21] - Neuromodulation global net sales increased by 15.5% as reported and 16.2% operationally, with organic growth at 3.7%[21] - Cardiology global net sales increased by 20.1% as reported, with operational and organic growth of 22%[23] - Electrophysiology global net sales increased by 121.9% as reported, with operational and organic growth of 124.6%[23]